Every Form 4 that BioCardia, Inc. (BCDA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCDA filings page.
BioCardia, Inc. President and CEO Peter Altman purchased 1,000 shares of common stock on September 29, 2026, at a weighted-average price of $1.03 per share. The trades ranged from $1.02 to $1.05 per share. His direct holdings following the purchase were 384,885 shares; no Rule 10b5-1 plan is reported.
BioCardia, Inc. director and President and CEO Peter Altman purchased 1,900 shares of common stock on September 23, 2026, at a reported weighted average price of $1.05 per share. The purchase consisted of multiple trades ranging from $1.04 to $1.08 per share. His reported direct holdings after the purchase were 383,885 shares. No Rule 10b5-1 plan is reported.
BioCardia, Inc. (BCDA) reported that President and CEO Peter Altman purchased 800 shares of common stock in a direct, open-market transaction on September 3, 2026, at a weighted average price of $1.09 per share, with individual trade prices ranging from $1.09 to $1.10. Following this purchase and a correction adding 70 previously omitted shares, he directly holds 381,985 shares of BioCardia common stock.
BioCardia, Inc. (BCDA) reported that its President and CEO, Peter Altman, purchased 5,400 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted average price of $0.93 per share. The trade was executed in multiple transactions between $0.92 and $0.97 per share, and Altman now directly holds 381,115 shares of BioCardia common stock. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
BioCardia, Inc. director and President & CEO Peter Altman purchased 1,900 shares of common stock on August 13, 2026 in an open-market transaction at a weighted average price of $0.92 per share, with individual trade prices ranging from $0.89 to $0.95. Following this purchase, he directly holds 375,785 shares of BioCardia common stock. The transaction was not reported as made under a Rule 10b5-1 trading plan.
BioCardia, Inc. reports that President and CEO Peter Altman purchased 5,000 shares of common stock on July 29, 2026 at a weighted average price of $0.78 per share, executed in multiple trades between $0.77 and $0.80. Following this transaction, he directly holds 373,885 shares.
BioCardia, Inc. director and President & CEO Peter Altman purchased 500 shares of Common Stock on July 17, 2026 at $0.83 per share in an open-market transaction. After this trade, he directly owns 368,885 shares of BioCardia common stock.
The filing’s Rule 10b5-1 trading-plan checkbox was not selected.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company common stock. He bought 2,800 shares at $0.88 on July 14, 2026 and 1,500 shares at $0.86 on July 15, 2026, bringing his direct holdings to 368,385 shares. The reported prices reflect weighted averages of multiple trades executed between $0.86 and $0.89 per share.
BioCardia, Inc. President and CEO Peter Altman reported a series of open‑market purchases of common stock. On July 8–10, 2026, he bought a total of 7,500 shares in three transactions, including 5,500 shares at $0.97, 1,000 shares at $0.90, and 1,000 shares at $0.94 per share. After these purchases, he directly owns 369,485 common shares. A footnote states that one transaction was executed in multiple trades between $0.92 and $1.05 per share and that the reported price is a weighted average, with full trade‑level details available upon request.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share. Following this transaction, he directly owns 361,985 shares. The trades were executed in multiple lots between $0.92 and $1.05 per share.
BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation. He was awarded options to acquire 8,000 shares of BioCardia common stock at an exercise price of $1.20 per share, expiring on July 6, 2036. All of these options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. Following this grant, he holds stock options covering a total of 23,573 shares directly.
BioCardia director Marvin Slosman received a stock option grant for 8,000 shares of common stock on the reported date. The option has an exercise price of $1.20 per share and expires on July 6, 2036, bringing his directly held stock options to 20,000 shares. All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant, provided he continues as a service provider through that date.
BioCardia, Inc. President and CEO Peter Altman reported routine equity compensation activity. On July 2, 2026, 54,606 shares of common stock were withheld by the company at $1.24 per share to cover income tax obligations on vested RSUs, and this did not represent a market sale by Altman. Following this tax-withholding disposition, he directly held 356,585 common shares. On July 6, 2026, he received a grant of stock options for 57,688 shares of common stock at a $1.20 exercise price, expiring on July 6, 2036, with vesting in 1/48th monthly installments beginning August 6, 2026, contingent on continued service, resulting in 147,903 options held after the grant.
BioCardia, Inc. Chief Financial Officer David McClung reported routine equity compensation and related tax withholding transactions. He received a grant of 41,501 stock options, each giving the right to buy common stock at $1.20 per share. The option vests in equal monthly installments over 48 months starting on August 6, 2026, and expires on July 6, 2036.
Separately, 23,125 shares of common stock were withheld by BioCardia at $1.24 per share to cover income tax obligations from restricted stock units that vested on June 29, 2026. The footnote specifies this withholding does not represent an open-market sale by McClung. After these transactions, he holds 114,245 common shares and 87,841 stock options directly.
BioCardia, Inc. Senior Vice President, Devices Edward M. Gillis received a stock option grant and had shares withheld for taxes in a routine compensation-related filing. He was granted options for 29,442 shares of common stock at an exercise price of $1.20 per share, vesting monthly over four years starting August 6, 2026. In a separate transaction, 17,269 common shares were withheld by BioCardia at $1.24 per share to cover income tax obligations on RSUs that vested June 29, 2026, which the company states does not represent a sale by him. Following these transactions, he directly holds 61,139 stock options and 54,126 common shares.
BioCardia director Andrew Scott Blank received an option grant for 8,000 shares of common stock. The stock option has an exercise price of $1.20 per share and expires on July 6, 2036. Following this grant, Blank holds 23,313 derivative securities representing options. According to the footnote, all 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, provided he continues as a service provider through that date.
BioCardia, Inc. director Jim L. Allen received a grant of 8,000 stock options to buy common stock at an exercise price of $1.20 per share. These options vest and become exercisable in full on the one-year anniversary of the grant date, if he continues as a service provider through that date.
After this award, he holds 23,313 stock options in total. This is a compensation-related grant rather than an open-market stock purchase or sale.
BioCardia, Inc. director Jay M. Moyes received a grant of stock options relating to 8,000 shares of common stock. These options have an exercise price of $1.20 per share and expire on July 6, 2036. All 8,000 options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, he holds a total of 23,573 stock options directly.
BioCardia, Inc. director Bill Facteau received a grant of stock options representing the right to buy 8,000 shares of common stock. The options have an exercise price of $1.20 per share and expire on July 6, 2036.
All 8,000 option shares vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. After this grant, his directly held option awards total 23,729 underlying shares.
Altman Peter reported acquisition or exercise transactions in this Form 4 filing.
BioCardia, Inc. reported that President and CEO Peter Altman received an equity compensation award in the form of restricted stock units. He was granted 110,625 shares of common stock at a reference value of $1.20 per share, bringing his direct holdings to 411,191 shares after the award. According to the footnote, these RSUs were granted as compensation in lieu of cash, and 100% of the units vested on June 29, 2026, providing him with an immediate fully vested equity stake.
BioCardia, Inc. reported that Chief Financial Officer David McClung acquired 60,483 shares of common stock through a grant of restricted stock units (RSUs) awarded as compensation in lieu of cash. Each RSU represents one share of common stock, and 100% of the RSUs vested on June 29, 2026. Following this award, McClung directly owns 137,370 shares of BioCardia common stock. This is a compensation-related equity grant rather than an open-market share purchase.
GILLIS EDWARD M reported acquisition or exercise transactions in this Form 4 filing.
BioCardia, Inc. reported that Senior Vice President, Devices, Edward M. Gillis received a grant of 39,521 shares of common stock on June 29, 2026. These were issued as restricted stock units awarded as compensation in lieu of cash, at a reference value of $1.20 per share. All of the RSUs vested on June 29, 2026, and his directly held common stock position increased to 71,395 shares after the grant.
BioCardia, Inc. director Simon H. Stertzer reported open‑market purchases of the company’s common stock. On June 22, he bought 70,200 shares at a reported weighted average price of $0.92 per share, in multiple trades ranging from $0.90 to $0.97 per share.
On June 23, he bought an additional 39,000 shares at a reported weighted average price of $1.00 per share, in trades ranging from $1.00 to $1.01 per share. After these transactions, his direct holdings rose to 166,338 shares, and the filing also lists several indirect holdings through family trusts and LLCs, including positions such as 591,054 shares held by Stertzer Holdings LLC.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s Common Stock. On June 17, 2026, he bought 1,500 shares at a weighted average price of $0.85 per share. On June 18, 2026, he bought an additional 800 shares at a weighted average price of $0.96 per share. Following these transactions, Altman directly owns 300,566 shares of BioCardia Common Stock.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,000 shares of common stock at $0.85 per share. After this transaction, he directly owns 298,266 BioCardia common shares, indicating a modest increase in his personal equity stake in the company.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s common stock. He bought 200 shares at $0.95 per share on May 19, 2026 and 1,500 shares at $0.92 per share on May 20, 2026. After these transactions, he directly owns 293,266 shares of BioCardia common stock.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,700 shares of Common Stock at a weighted average price of $0.92 per share. Following this transaction, he directly holds 291,566 shares. The trade was executed in multiple lots between $0.89 and $1.02 per share.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of common stock. He bought 5,100 shares at a weighted average price of $1.02 per share. Following this transaction, he directly owns 285,866 shares of BioCardia common stock.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,000 shares of the company’s Common Stock at $1.11 per share on April 29, 2026.
Following this transaction, he directly owns 280,766 shares of BioCardia common stock.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company stock. He bought a total of 1,000 shares of BioCardia common stock in two transactions at a weighted average price of $1.23 per share, increasing his direct holdings to 275,766 shares following these trades.
BioCardia, Inc. President and CEO Peter Altman bought additional company stock in two open‑market transactions. He purchased 600 shares of common stock on March 24, 2026 at an average price of $1.24 per share and 300 shares on March 25, 2026 at an average price of $1.22 per share.
Both trades were executed in multiple lots within disclosed price ranges, with reported prices reflecting weighted averages. Following these purchases, Altman directly owns 274,766 shares of BioCardia common stock.
BioCardia, Inc. President and CEO Peter Altman, who is also a director, reported buying additional common stock of the company. On 02/04/2026, he purchased 5,000 shares of BioCardia common stock at a price of $1.13 per share.
Following this transaction, Altman beneficially owned 273,866 shares of BioCardia common stock, held in direct ownership. The filing was made on a Form 4, which reports insider trades by company officers and directors.
BioCardia, Inc. insider activity: President and CEO Peter Altman reported open‑market purchases of the company’s common stock on two consecutive days in January. On January 20, 2026, he bought 600 shares at a weighted average price of $1.32 per share, in multiple trades executed between $1.31 and $1.33. On January 21, 2026, he purchased an additional 300 shares at a weighted average price of $1.34 per share, in trades executed between $1.34 and $1.35. Following these transactions, he directly owned 268,866 shares of BioCardia common stock.
BioCardia, Inc.'s president, CEO and director reported open-market purchases of the company’s common stock. On December 16, 2025, the reporting person bought 200 shares of BioCardia common stock at a weighted average price of $1.37 per share, executed in multiple trades between $1.28 and $1.46 per share. On December 17, 2025, they bought an additional 900 shares at a weighted average price of $1.30 per share, with individual trade prices ranging from $1.23 to $1.38 per share. After these transactions, the reporting person beneficially owned 267,966 shares of BioCardia common stock, held directly.
BioCardia, Inc. Senior Vice President, Devices reported equity compensation activity. On December 8, 2025, the executive acquired 38,078 restricted stock units (RSUs), each equal to one share of common stock awarded as compensation in lieu of cash, with 100% of the RSUs vesting on that date. To cover income tax withholding for the vested RSUs, 15,172 shares were withheld by BioCardia, which is not a sale by the executive. After these transactions, the executive beneficially owned 31,874 shares of common stock. The filing also reports a grant of a stock option for 20,000 shares at an exercise price of $1.37 per share, expiring on December 8, 2035, vesting as to 1/48th of the shares starting January 8, 2026 and monthly thereafter, contingent on continued service.
BioCardia, Inc. director reports new stock option grant
A BioCardia, Inc. director filed a Form 4 reporting the grant of a stock option on 12/08/2025. The option gives the right to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. According to the filing, all of these shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date.
After this grant, the reporting person beneficially owns 15,313 derivative securities, held directly. The option is shown with an expiration date of 12/08/2035, providing a long-term window during which the director may choose to exercise the option once vested.
BioCardia, Inc. reported an insider equity award to one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option vests and becomes fully exercisable on the one-year anniversary of the grant date, so long as the director continues as a service provider through that date, and it expires on 12/08/2035. Following this grant, the director beneficially owns 15,729 derivative securities, held directly.
BioCardia, Inc. director receives new stock option grant. A company director reported receiving a stock option to buy 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share, granted on 12/08/2025.
According to the filing, all of the shares under this option vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues as a service provider through that date. After this grant, the reporting person beneficially owns 15,573 derivative securities (stock options) on a direct basis, with the reported option expiring on 12/08/2035.
BioCardia, Inc. reported an insider equity award for one of its directors. On 12/08/2025, the director received a stock option to purchase 12,000 shares of BioCardia common stock at an exercise price of $1.37 per share. The option is classified as a derivative security because it represents the right to buy common stock in the future at a fixed price.
All 12,000 option shares are scheduled to vest and become exercisable on the one-year anniversary of the grant date, as long as the director continues to serve as a service provider through that date. The option expires on 12/08/2035 if not exercised earlier. After this grant, the director beneficially owns 12,000 derivative securities directly in the form of this stock option.